Holen Sie sich die Stockscreener-App
1.07
1.90%
0.02
Handel nachbörslich:
1.05
-0.02
-1.87%
Schlusskurs vom Vortag:
$1.05
Offen:
$1.04
24-Stunden-Volumen:
124.51K
Relative Volume:
0.74
Marktkapitalisierung:
$6.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.07M
KGV:
-0.1419
EPS:
-7.54
Netto-Cashflow:
$-7.34M
1W Leistung:
-1.83%
1M Leistung:
+4.90%
6M Leistung:
-2.73%
1J Leistung:
-38.15%
1-Tages-Spanne:
$1.00
$1.07
1-Wochen-Bereich:
$1.00
$1.16
52-Wochen-Spanne:
$0.765
$4.1699
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Firmenname
Adial Pharmaceuticals Inc
Sektor
Branche
Telefon
434-422-9800
Adresse
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Vergleichen Sie ADIL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
1.07 | 6.85M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2018-10-30 | Eingeleitet | Maxim Group | Buy |
| 2018-10-11 | Eingeleitet | Dawson James | Buy |
Adial Pharmaceuticals Inc Aktie (ADIL) Neueste Nachrichten
Adial Pharmaceuticals’ New Purchase Agreement with Alumni Capital - TipRanks
Adial Pharmaceuticals (NASDAQ:ADIL) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 71.7% - Defense World
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals revises CEO's compensation package By Investing.com - Investing.com South Africa
Adial Pharmaceuticals revises CEO's compensation package - Investing.com India
Adial Pharmaceuticals secures new patent for AUD therapy By Investing.com - Investing.com South Africa
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations - AOL
Adial Pharmaceuticals, Inc. Updates on Onward Phase 3 Pivotal Trial - Marketscreener.com
Adial Pharmaceuticals secures new patent for AUD therapy - Investing.com
Adial Pharmaceuticals Granted Key U.S. Patent for the - GlobeNewswire
Adial Pharmaceuticals Secures Key Patent for Alcohol Use Disorder Treatment Technology - StockTitan
Alcohol Use Disorder Treatment Market Report Analysis - openPR
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Growth in Short Interest - Defense World
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know - MSN
Equities Analysts Offer Predictions for ADIL FY2024 Earnings - Defense World
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adial Pharmaceuticals (NASDAQ:ADIL) Coverage Initiated at Rodman & Renshaw - Defense World
RODMAN&RENSHAW Upgrades Adial Pharmaceuticals (NASDAQ:ADIL) to “Strong-Buy” - Defense World
ARMISTICE CAPITAL, LLC Acquires New Stake in Adial Pharmaceutica - GuruFocus.com
Rodman & Renshaw sets stock target, buy rating on Adial Pharma, cites potential - Investing.com India
U.S. STOCKS Oklo, Adial Pharma, Sonos - XM
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder - AOL
Adial Pharmaceuticals completes key study for FDA meeting - Investing.com
Adial Pharmaceuticals Announces Positive Topline Results - GlobeNewswire
Adial Pharma's AD04 Drug Hits Key Milestones in Alcohol Use Disorder Treatment Study | ADIL Stock News - StockTitan
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharma Reports Mixed Q3: AUD Drug Study Advances Despite Widening Losses | ADIL Stock News - StockTitan
Adial Pharmaceuticals Approves Strategic Changes at Annual Meeting - TipRanks
Adial Pharmaceuticals Appoints Vinay Shah as CFO - Defense World
Adial Pharmaceuticals names new CFO amid strategic growth By Investing.com - Investing.com Australia
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - GlobeNewswire
Adial Pharmaceuticals names new CFO amid strategic growth - Investing.com
Adial Pharma Taps Veteran CFO with $150M+ Fundraising Track Record | Key Executive Move | ADIL Stock News - StockTitan
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference - The Manila Times
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate - AOL
Adial Pharmaceuticals patent expands for alcohol disorder drug - Investing.com
Adial Pharmaceuticals patent expands for alcohol disorder drug By Investing.com - Investing.com Canada
Adial Pharmaceuticals Receives Notice of Allowance for U.S. - GlobeNewswire
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery - GlobeNewswire
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 46.2% in September - Defense World
Analyzing ADI’s price-to-book ratio for the last quarter - US Post News
Adial Pharmaceuticals completes key study stage for AUD drug - Investing.com
Adial Pharmaceuticals Announces Database Lock in - GlobeNewswire
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - StockTitan
Analog Devices Inc. (ADI) Stock: A Year of Declines and Increases - The InvestChronicle
MQS Management LLC Increases Stock Position in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Addex Therapeutics Reports Profitable H1 2024 - TipRanks
Finanzdaten der Adial Pharmaceuticals Inc-Aktie (ADIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):